A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
← catalyst calendarSponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (industry) · ZNTL — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
274actual
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-11-01 | actual | When the study began enrolling |
| Primary completion | 2025-05-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-06 | actual | The whole study's end, after follow-up |
| First posted | 2019-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Intervention
- Drug: Azenosertib — also filed as ZN-c3
Primary outcomes
what the primary-completion date above is the date OFDose Escalation
measured Through completion, average of 1 year
Food Effect Cohort
measured Through completion, approx 6 months
Food Effect Cohort
measured Through completion, approximately 6 months
Food Effect Cohort
measured Through completion approximately 6 month
Food Effect Cohort
measured Through completion, approximately 6 mth
Dose Expansion
measured Through completion, approximately 43 month
Permalink · ZNTL's whole pipeline · Catalyst calendar · Every registered study · What changed